Despite technological advances in surgery and radiotherapy for patients who suffer from oral squamous cell carcinoma (OSCC), the survival rate has remained un-improved during the last two decades indicating our ability to treat patients has reached a plateau. We have reported that proteasome inhibition induced ER stress CHOP-mediated apoptosis in HNSCC cell lines, including several that are cisplatin-resistent. ER stress leads to a physiological response known as the unfolded protein response (UPR) which consists of distinct parallel genetic programs that attempt to restore homeostatic protein folding or lead to apoptosis if the stress is prolonged or robust. We hypothesized that we could use high throughput screening (HTS) with diverse chemical libraries to identify novel small molecule CHOP activators to induce apoptosis in OSCC cells. We have developed a Complementary cell-based assay using stably transfected CMQ-K1 cells that individually report on the PERK/elF2D/CH0P (apoptotic) and the IRE1/XBP1 (adaptive) pathways of the UPR. Identifying compounds that specifically activate only PERK/elF2n/CHOP and not 1RE1/XBP1 has allowed us to aile out many compounds that generally perturb protein folding. 65 hit compounds have been identified that activated the CHOP but not the XBP1 reporter with chemical signatures amenable for synthetic analoging and therapeutic development. We propose to test the ability of these 65 Compounds along with commercially available analog series to induce CHOP expression and apoptosis in a panel of OSCC cells. The hiost promising candidates will be evaluated in vivo in a well-characterized rbd^ht xenograft model. The long-term objectives of the proposed studies are to elucidate the ability of these novel small molecules to induce CHOP and inhibit growth or induce apoptosis in OSCC cells and to further screen very large diverse libraries of chemical probes with our complementary cell-based screen, Small molecule UPR agonisits identified through these studies will pfovide a convenient cost-effective rneans of treating patients suffering from a disease for which therapies are limited to minimally effective chemotherapies, damaging radiation or painful surgeries that often interfere with their ability to speak, chew or even breathe.

Public Health Relevance

The suivival rate for patients with tumors in the head and neck region has not improved in ov6r 20 years. We screened a chemical library of 66,000 small molecules to identify novel drug-like compounds. The proposed studies will detemnine the ability of hits from this screen to interfere with the growth of or kill head and neck tumor cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Transition Award (R00)
Project #
5R00DE019678-05
Application #
8403386
Study Section
Special Emphasis Panel (NSS)
Program Officer
Venkatachalam, Sundaresan
Project Start
2011-02-01
Project End
2015-01-31
Budget Start
2013-02-01
Budget End
2015-01-31
Support Year
5
Fiscal Year
2013
Total Cost
$230,671
Indirect Cost
$78,914
Name
Wayne State University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Xi, Y; Garshott, D M; Brownell, A L et al. (2015) Cantharidins induce ER stress and a terminal unfolded protein response in OSCC. J Dent Res 94:320-9
Limesand, Kirsten H; Chibly, Alejandro Martinez; Fribley, Andrew (2013) Impact of targeting insulin-like growth factor signaling in head and neck cancers. Growth Horm IGF Res 23:135-40